Anti-p16 antibody clone JAP16 has been developed and validated for IHC detection of p16 (INK4A) tumor suppressor in routine-fixed FFPE tissue sections.
p16 is a strong negative regulator of cell proliferation and a critical tumor suppressor protein. It is the principal member of the INK4 family of cyclin-dependent kinase (CDK) inhibitors. During cell cycle progression, p16 specifically inhibits the formation of an active CDK4/6 kinase complex and thus, phosphorylation of retinoblastoma (Rb) protein. Since phosphorylation of Rb protein is a vital step for G1-to-S phase transition, p16-binding to the upstream kinase leads to cell cycle arrest.
p16 inactivation has been reported in nearly 50% of all human cancers, e.g.: head and neck, esophagus, biliary tract, liver, lung, bladder, colon and breast carcinomas, leukemia, lymphomas, glioblastomas. Besides downregulation, p16 overexpression has been observed in HPV (human papilloma virus)-related tumors such as cervical cancer. HPV oncoproteins target the p16-Rb pathway by E7 induced degradation of the retinoblastoma protein. Here, the overexpression of p16 reflects an unsuccessful attempt to stop cell proliferation in HPV-related tumors.
p16 is an important immunohistochemical (IHC) marker in gynecologic pathology.
Klonalität:
Monoclonal
Klon-Bezeichnung:
[IHC116]
Isotyp:
IgG1
Tag:
unconjugated
UniProt:
Q8N726
Formulierung:
< 0.1% NaN3, 1% BSA, concentrate, in Tris buffer (pH 7.3-7.7), ProteinA/G purified antibody
Target-Kategorie:
p16 (CDKN2A)
Antibody Type:
Monoclonal Antibody
Application Verdünnung:
Immunohistochemistry (IHC): 1:100 – 1:400
p16_Serous-ovarian-carcinoma
p16_Phyllodes-tumor-of-breast
p16_Endometrioid-ovarian-carcinoma
p16_Cervical-adenocarcinoma
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
